Active substance
Carvedilol
- SFDA 20
- US FDA 21
- Health Canada 28
- US price lines 8
- NHS prices 4
- WHO EML 4
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CARVIDOL 25 MG TAB | 25 mg | Tablet · Oral use | 30 Blister | SAR 47.25 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CARVIDOL 6.25MG TABLET | 6.25 mg | Tablet · Oral use | 30 Blister | SAR 26.40 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| DILATREND 25MG TABLET | 25 mg | Tablet · Oral use | 30 Blister | SAR 47.25 | Generic · Prescription | CHEPLAPHARM Arzneimittel GmbH | Valid |
| DILATREND 6.25 MG TABLET | 6.25 mg | Tablet · Oral use | 30 Blister | SAR 27.80 | Generic · Prescription | CHEPLAPHARM Arzneimittel GmbH | Valid |
| RIACAVILOL 12.5 MG TAB | 12.5 mg | Film-coated tablet · Oral use | 30 Blister | SAR 24.10 | Generic · Prescription | RIYADH PHARMA | Valid |
| RIACAVILOL 25MG TABLET | 25 mg | Film-coated tablet · Oral use | 30 Blister | SAR 42.50 | Generic · Prescription | RIYADH PHARMA | Valid |
| RIACAVILOL 6.25 MG TABLET | 6.25 mg | Film-coated tablet · Oral use | 30 Blister | SAR 15.95 | Generic · Prescription | RIYADH PHARMA | Valid |
| Ravildo 12.5 mg F.C Tablets | 12.5 mg | Film-coated tablet · Oral use | 30 Bottle | SAR 17.60 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| Ravildo 25 mg F.C Tablets | 25 mg | Film-coated tablet · Oral use | 30 Bottle | SAR 26.65 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| Ravildo 3.125 mg F.C Tablets | 3.125 mg | Film-coated tablet · Oral use | 30 Bottle | SAR 6.45 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| Ravildo 6. 25 mg F.C Tablets | 6.25 mg | Film-coated tablet · Oral use | 30 Bottle | SAR 12.90 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| CARVIDOL 12.5 MG TAB | 12.5 mg | Tablet · Oral use | 30 Blister | SAR 27.90 | NCE · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| CARVOLCAN 12.5 MG TABLET | 12.5 mg | Tablet · Oral use | 100 Blister | SAR 66.00 | Generic · Prescription | PHARMASCIENCE INC. | Withdrawn by MAH · Not Marketed |
| CARVOLCAN 12.5 MG TABLET | 12.5 mg | Tablet · Oral use | 30 Blister | SAR 19.55 | Generic · Prescription | PHARMASCIENCE INC. | Withdrawn by MAH · Not Marketed |
| CARVOLCAN 25 MG TABLET | 25 mg | Tablet · Oral use | 100 Blister | SAR 107.00 | Generic · Prescription | PHARMASCIENCE INC. | Withdrawn by MAH · Not Marketed |
| CARVOLCAN 25 MG TABLET | 25 mg | Tablet · Oral use | 30 Blister | SAR 29.60 | Generic · Prescription | PHARMASCIENCE INC. | Withdrawn by MAH · Not Marketed |
| CARVOLCAN 6.25 MG TABLET | 6.25 mg | Tablet · Oral use | 30 Blister | SAR 14.35 | Generic · Prescription | PHARMASCIENCE INC. | Withdrawn by MAH · Not Marketed |
| CARVOLCAN 6.25 MG TABLET | 6.25 mg | Tablet · Oral use | 100 Blister | SAR 47.85 | Generic · Prescription | PHARMASCIENCE INC. | Withdrawn by MAH · Not Marketed |
| DILATREND 25MG TABLET | 25 mg | Tablet · Oral use | 30 Blister | SAR 52.05 | Generic · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
| DILATREND 6.25 MG TABLET | 6.25 mg | Tablet · Oral use | 30 Blister | SAR 27.80 | Generic · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ARRHYTHMIA; ATRIAL FIBRILLATION; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; HYPERTENSION; NON-ST WAVE ELEVATED MYOCARDIAL INFARCTION (NSTEMI); ST-WAVE ELEVATED MYOCARDIAL INFARCTION (STEMI); VENTRICULAR TACHYCARDIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| COREG | 25MG; 12.5MG; 6.25MG; 3.125MG | tablet · oral | WAYLIS THERAP | Prescription | 14 Sep 1995 |
| COREG CR | 10MG; 20MG; 40MG; 80MG | capsule, extended release · oral | WAYLIS THERAP | Prescription | 20 Oct 2006 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | TEVA | Prescription | 5 Sep 2007 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | RISING | Prescription | 5 Sep 2007 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | CHARTWELL MOLECULAR | Prescription | 5 Sep 2007 |
| CARVEDILOL | 6.25MG; 12.5MG; 25MG; 3.125MG | tablet · oral | ZYDUS PHARMS USA INC | Prescription | 5 Sep 2007 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | RUBICON RESEARCH | Prescription | 5 Sep 2007 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | SANDOZ | Prescription | 5 Sep 2007 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | GLENMARK PHARMS LTD | Prescription | 5 Sep 2007 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | AUROBINDO PHARMA | Prescription | 5 Sep 2007 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | REGCON HOLDINGS | Prescription | 5 Sep 2007 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | MLV | Prescription | 22 Dec 2009 |
| CARVEDILOL PHOSPHATE | 10MG; 20MG; 40MG; 80MG | capsule, extended release · oral | SUN PHARM INDUSTRIES | Prescription | 25 Oct 2017 |
| CARVEDILOL PHOSPHATE | 10MG; 20MG; 40MG; 80MG | capsule, extended release · oral | IMPAX LABS INC | Prescription | 7 May 2018 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | SUN PHARM INDS LTD | Discontinued | 5 Sep 2007 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | SCIEGEN PHARMS | Discontinued | 5 Sep 2007 |
| CARVEDILOL | 6.25MG; 12.5MG; 25MG; 3.125MG | tablet · oral | SUN PHARM INDS INC | Discontinued | 5 Sep 2007 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | TARO | Discontinued | 5 Sep 2007 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | LUPIN | Discontinued | 5 Sep 2007 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | HIKMA | Discontinued | 7 Sep 2007 |
| CARVEDILOL | 3.125MG; 6.25MG; 12.5MG; 25MG | tablet · oral | PLIVA HRVATSKA DOO | Discontinued | 30 Oct 2007 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AURO-CARVEDILOL | 02418495 | 3.125 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-CARVEDILOL | 02418509 | 6.25 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-CARVEDILOL | 02418517 | 12.5 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-CARVEDILOL | 02418525 | 25 MG | TABLET · ORAL | AURO PHARMA INC |
| CARVEDILOL | 02248752 | 3.125 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| CARVEDILOL | 02248753 | 6.25 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| CARVEDILOL | 02248754 | 12.5 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| CARVEDILOL | 02248755 | 25 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| CARVEDILOL | 02324504 | 3.125 MG | TABLET · ORAL | PRO DOC LIMITEE |
| CARVEDILOL | 02324512 | 6.25 MG | TABLET · ORAL | PRO DOC LIMITEE |
| CARVEDILOL | 02324520 | 12.5 MG | TABLET · ORAL | PRO DOC LIMITEE |
| CARVEDILOL | 02324539 | 25.0 MG | TABLET · ORAL | PRO DOC LIMITEE |
| CARVEDILOL | 02364913 | 3.125 MG | TABLET · ORAL | SANIS HEALTH INC |
| CARVEDILOL | 02364921 | 6.25 MG | TABLET · ORAL | SANIS HEALTH INC |
| CARVEDILOL | 02364948 | 12.5 MG | TABLET · ORAL | SANIS HEALTH INC |
| CARVEDILOL | 02364956 | 25 MG | TABLET · ORAL | SANIS HEALTH INC |
| JAMP-CARVEDILOL | 02368897 | 3.125 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP-CARVEDILOL | 02368900 | 6.25 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP-CARVEDILOL | 02368919 | 12.5 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP-CARVEDILOL | 02368927 | 25 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| PMS-CARVEDILOL | 02245914 | 3.125 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PMS-CARVEDILOL | 02245915 | 6.25 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PMS-CARVEDILOL | 02245916 | 12.5 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PMS-CARVEDILOL | 02245917 | 25 MG | TABLET · ORAL | PHARMASCIENCE INC |
| TEVA-CARVEDILOL | 02252309 | 3.125 MG | TABLET · ORAL | TEVA CANADA LIMITED |
3 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CARVEDILOL 12.5 MG TABLET | $0.0216 | per EA | 23 Sep 2026 |
| US NADAC | CARVEDILOL 25 MG TABLET | $0.03235 | per EA | 7 Oct 2026 |
| US NADAC | CARVEDILOL 3.125 MG TABLET | $0.01664 | per EA | 7 Oct 2026 |
| US NADAC | CARVEDILOL 6.25 MG TABLET | $0.01794 | per EA | 7 Oct 2026 |
| US NADAC | CARVEDILOL ER 10 MG CAPSULE | $6.52042 | per EA | 23 Sep 2026 |
| US NADAC | CARVEDILOL ER 20 MG CAPSULE | $6.73661 | per EA | 23 Sep 2026 |
| US NADAC | CARVEDILOL ER 40 MG CAPSULE | $6.37871 | per EA | 23 Sep 2026 |
| US NADAC | CARVEDILOL ER 80 MG CAPSULE | $5.79162 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Carvedilol 12.5mg tablets | £3.74 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Carvedilol 25mg tablets | £3.50 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Carvedilol 3.125mg tablets | £2.05 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Carvedilol 6.25mg tablets | £5.29 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 12.1. Antianginal medicines · core
Therapeutic equivalent to bisoprolol for Angina pectoris - 12.3. Antihypertensive medicines · core
Therapeutic equivalent to bisoprolol for Essential hypertension - 12.2. Antiarrhythmic medicines · core
Therapeutic equivalent to bisoprolol for Cardiac arrhythmia - 12.4. Medicines used in heart failure · core
Therapeutic equivalent to bisoprolol for Heart failure
Safety signals and safety-related labeling changes
- US FDA 26 Jul 2023 COREG — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 26 Jul 2023 COREG CR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.